San Diego, CA / May 18, 2009 / –
Dr. Kenneth Kim, CEO of West Coast Clinical Trials (WCCT) presented a poster at the International Conference of the American Thoracic Society entitled, “Effect of Adjustable-Dose (AD) Budesonide/Formoterol Pressurized Metered-Dose Inhaler (pMDI), Fixed-Dose (FD) Budesonide/Formoterol pMDI, and FD Fluticasone/Salmeterol Dry Powder Inhaler (DPI) on Predose FEF 25%-75%” . For additional information regarding this study, please contact AstraZeneca.
About West Coast Clinical Trials, LLC
WCCT is an independent early phase clinical CRO with a 120-bed phase I facility with 10 telemetry equipped beds located in southern California. WCCT has a unique focus on Ethno-bridging studies along with extensive experience with healthy volunteer and specialty trials (allergy, asthma, infectious disease, pediatric, renal and vaccines). For more information, visit our Web site at
5630 Cerritos Ave.
Cypress, CA 90630 USA
Phone: (714) 252-0700